Skip to content
DraconiticResearch
Search Sources API
179,152 studies31 sourcesUpdated 28 min ago
Peer-reviewedCC BY 4.0International Journal of Molecular Sciences

Steroidomic Differences Among Clozapine, Olanzapine, and Risperidone in Male Patients with First-Episode Psychosis, Including a Treatment-Resistant Schizophrenia Subgroup

  • Karel Valeš1,2
  • Kristína Holubová1
  • Filip Španiel1,2
  • Petra Fürstová1
  • Miloš Petrović3
  • Marta Velíková4
  • Martin Hill4
4 affiliations
  1. 1National Institute of Mental Health, Topolova 748, 250 67 Klecany, Czech Republic
  2. 2Third Faculty of Medicine, Charles University in Prague, Ruská, 871 00 Prague, Czech Republic
  3. 3Clinic for Internal Medicine, Clinical Hospital Centre, Dragisa Misovic-Dedinje, 11000 Belgrade, Serbia
  4. 4Institute of Endocrinology, 110 00 Prague, Czech Republic
Read full textPDFDOICite

Abstract

Clozapine (Clo) is the most effective antipsychotic for treatment-resistant schizophrenia (TRS), yet the mechanisms underlying its unique clinical profile remain insufficiently understood. Neuroactive steroids (NASs) influence neuronal excitability, neuroplasticity, inflammation, and stress responses—domains disrupted in schizophrenia—and may contribute to antipsychotic pharmacodynamics. This pilot study examined whether Clo exhibits a distinctive steroidomic pattern compared with olanzapine (Ola) and risperidone (Ris) in male patients with first-episode psychosis, including a clinically defined TRS subgroup receiving Clo. Serum collected after group-specific treatment durations (Clo: 17.7 ± 12.4; Ola: 13.9 ± 1.9; Ris: 12.9 ± 1.3 months) was analyzed by GC–MS/MS, with steroidogenic enzyme activities inferred from precursor–product molar ratios as proxies of metabolic balance. Statistical evaluation included age-adjusted ANCOVA, OPLS, multiple regression, and trend-based analysis of coordinated pathway-level shifts. Although Ola increased several steroid concentrations, its overall and unconjugated trends did not differ significantly from Clo (p = 0.515 and p = 0.409). At the multivariate level, however, the two profiles were significantly discriminated (OPLS: R2Y = 50.8%, CV-ANOVA p = 0.011), indicating that the difference lies in the coordinated pattern rather than the global magnitude of change. Clo showed a distinctive exploratory pattern: lower DHEA, higher 5α-reduced pregnane NAS, altered androgen turnover, reduced CYP17A1 lyase proxy activity, and a mild but statistically significant increase in the cortisol-to-cortisone ratio, and was clearly distinguished from Ris by broad steroid increases. This may indicate a shift toward a profile with potential GABAergic and neuroprotective features, although interpretations remain exploratory given the small, cross-sectional, male-only sample and the non-independence of steroid pathways. Neurosteroidogenesis may thus contribute to antipsychotic response variability and offer candidate biomarkers, warranting validation in larger longitudinal studies.

Related

  1. Rapid Resolution of Apophenic Psychosis With Low-Dose Olanzapine in Very Late-Onset Schizophrenia-Like Psychosis
    Yusuf Jamal, Mohamed A Mohamed, Nauman Malik
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Neuroanatomical Subtypes of Schizophrenia Reveal Divergent Atrophy Trajectories and Distinct Associations with Long-Term Clozapine Use
    Xiao Chang, Yuchao Jiang, Bochao Danae Lin +14
    Schizophrenia BulletinPeer-reviewedPublisher termsFull textPsychiatry & mental healthPMC
  3. Clozapine Augmentation Strategies and Clinical Predictors of Prolonged Tertiary Hospitalization in Clozapine-Resistant Schizophrenia: a Retrospective Cohort Study.
    Kaitlyn Baldwin, William G Honer, Reza Shahbazi +4
    Schizophrenia bulletinPeer-reviewedCC BY-NCFull textPsychiatry & mental healthEurope PMCPMC
  4. Cariprazine Augmentation and Sustained Remission of Physical Aggression in Clozapine-Treated Treatment-Resistant Schizophrenia: A Case Report.
    Juhani Leijala, Antti Mustonen
    Case reports in psychiatryPeer-reviewedCC BYFull textPsychiatry & mental healthEurope PMC
  5. Effect of Blonanserin on Neurotrophic Factors in Patients With Non-Responsive First-Episode Schizophrenia Treated With Early Risperidone Monotherapy-A Randomized Controlled Trial.
    Yaxue Wei, Yanting Liu, Lili Cai +5
    International journal of methods in psychiatric researchPeer-reviewedCC BY-NC-NDFull textPsychiatry & mental healthEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{vales2026steroidomic,
  title = {{Steroidomic Differences Among Clozapine, Olanzapine, and Risperidone in Male Patients with First-Episode Psychosis, Including a Treatment-Resistant Schizophrenia Subgroup}},
  author = {Karel Valeš and Kristína Holubová and Filip Španiel and Petra Fürstová and Miloš Petrović and Marta Velíková and Martin Hill},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  month = oct,
  doi = {10.3390/ijms27198909},
  url = {https://www.mdpi.com/1422-0067/27/19/8909},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Steroidomic Differences Among Clozapine, Olanzapine, and Risperidone in Male Patients with First-Episode Psychosis, Including a Treatment-Resistant Schizophrenia Subgroup
AU  - Karel Valeš
AU  - Kristína Holubová
AU  - Filip Španiel
AU  - Petra Fürstová
AU  - Miloš Petrović
AU  - Marta Velíková
AU  - Martin Hill
PY  - 2026
DA  - 2026/10/07
JO  - International Journal of Molecular Sciences
DO  - 10.3390/ijms27198909
UR  - https://www.mdpi.com/1422-0067/27/19/8909
AB  - Clozapine (Clo) is the most effective antipsychotic for treatment-resistant schizophrenia (TRS), yet the mechanisms underlying its unique clinical profile remain insufficiently understood. Neuroactive steroids (NASs) influence neuronal excitability, neuroplasticity, inflammation, and stress responses—domains disrupted in schizophrenia—and may contribute to antipsychotic pharmacodynamics. This pilot study examined whether Clo exhibits a distinctive steroidomic pattern compared with olanzapine (Ola) and risperidone (Ris) in male patients with first-episode psychosis, including a clinically defined TRS subgroup receiving Clo. Serum collected after group-specific treatment durations (Clo: 17.7 ± 12.4; Ola: 13.9 ± 1.9; Ris: 12.9 ± 1.3 months) was analyzed by GC–MS/MS, with steroidogenic enzyme activities inferred from precursor–product molar ratios as proxies of metabolic balance. Statistical evaluation included age-adjusted ANCOVA, OPLS, multiple regression, and trend-based analysis of coordinated pathway-level shifts. Although Ola increased several steroid concentrations, its overall and unconjugated trends did not differ significantly from Clo (p = 0.515 and p = 0.409). At the multivariate level, however, the two profiles were significantly discriminated (OPLS: R2Y = 50.8%, CV-ANOVA p = 0.011), indicating that the difference lies in the coordinated pattern rather than the global magnitude of change. Clo showed a distinctive exploratory pattern: lower DHEA, higher 5α-reduced pregnane NAS, altered androgen turnover, reduced CYP17A1 lyase proxy activity, and a mild but statistically significant increase in the cortisol-to-cortisone ratio, and was clearly distinguished from Ris by broad steroid increases. This may indicate a shift toward a profile with potential GABAergic and neuroprotective features, although interpretations remain exploratory given the small, cross-sectional, male-only sample and the non-independence of steroid pathways. Neurosteroidogenesis may thus contribute to antipsychotic response variability and offer candidate biomarkers, warranting validation in larger longitudinal studies.
SN  - 1422-0067
ER  -